Sagar Rachel, Walther-Jallow Lilian, David Anna L, Götherström Cecilia, Westgren Magnus
1Institute for Women's Health, University College London, 86-96 Chenies Mews, London, WC1E 6HX UK.
2Department of Clinical Science, Intervention and Technology, K57, Division of Obstetrics and Gynecology, Karolinska University Hospital Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden.
Curr Stem Cell Rep. 2018;4(1):61-68. doi: 10.1007/s40778-018-0118-8. Epub 2018 Feb 15.
The aim of the study is to provide an overview on the possibility of treating congenital disorders prenatally with mesenchymal stromal cells (MSCs).
MSCs have multilineage potential and a low immunogenic profile and are immunomodulatory and more easy to expand in culture. Their ability to migrate, engraft and differentiate, or act via a paracrine effect on target tissues makes MSCs candidates for clinical therapies. Fetal and extra-fetal MSCs offer higher therapeutic potential compared to MSCs derived from adult sources.
MSCs may be safely transplanted prenatally via ultrasound-guided injection into the umbilical cord. Due to these characteristics, fetal MSCs are of great interest in the field of in utero stem cell transplantation for treatment of congenital disease.
本研究旨在概述使用间充质基质细胞(MSCs)进行产前治疗先天性疾病的可能性。
MSCs具有多向分化潜能且免疫原性低,具有免疫调节作用且在培养中更易于扩增。它们的迁移、植入和分化能力,或通过旁分泌作用作用于靶组织的能力使MSCs成为临床治疗的候选者。与源自成人的MSCs相比,胎儿和胎儿外MSCs具有更高的治疗潜力。
MSCs可以通过超声引导注射安全地进行产前移植到脐带中。由于这些特性,胎儿MSCs在子宫内干细胞移植治疗先天性疾病领域引起了极大的兴趣。